News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Onconova Therapeutics Inc. Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at American Association for Cancer Research 2013 Annual Meeting


4/10/2013 6:44:44 AM

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research (AACR) Annual Meeting.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES